Grant: Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators
McMaster University
$100,000.00
The role of intestinal microbiota in host responses to dietary gluten and to gluten binders.
FY 2011-12
Summary
Celiac Disease (CD) is a common digestive disorder affecting children and adults. When people that have the genes for CD (HLA-DQ2 or DQ8) eat gluten (contained in cereals), it creates an inflammatory reaction that causes damage to the lining of the gut wall and does not allow food to be properly absorbed. People with CD also suffer from osteporosis, depression, infertility, and have increased risk to develop Type 1 diabetes and some cancers. In Canada, 330,000 persons currently have CD and the number of affected people continues to rise. We do not understand the reasons behind this increase. Our results using a unique animal model of gluten sensitivity that express the human genes that predispose to CD, suggest it may relate to changes in the microbes that reside in our gut. Thus, we propose to investigate the role of gut bacteria in gluten intolerance. We will use gluten-sensitive mice with no bacteria (germ-free) and we will colonize them with gut bacteria from patients with CD and healthy people.
There is no treatment for CD except for the gluten-free diet. This is a life-long commitment, not always effective and is very expensive for families as gluten-free foods are costly and not covered by the health care system. Moreover, it is not recommended in milder forms of gluten intolerance. This increases the possibility to progress from milder gluten intolerance to the severe condition of CD. We have developed a novel drug that binds to gluten in the gut lumen. We propose to investigate the mechanisms of action of this gluten binder in gluten-sensitive mice. Availability of safe therapies for gluten intolerance will add flexibility to the diet and increase the quality of life of gluten-sensitive patients as well as reduce the risks and health care costs associated with complications of CD and associated diseases such as Type 1 diabetes and cancer.
Department
Program
Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
247109
Name
Verdu Elena F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Nutrition, Food & Health
Projecttitle
The role of intestinal microbiota in host responses to dietary gluten and to gluten binders.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators
Keyworddelim
Gluten Binding Polymers; Gluten-Sensitivity Mouse Models; Intestinal Microbiota
Abstract
Celiac Disease (CD) is a common digestive disorder affecting children and adults. When people that have the genes for CD (HLA-DQ2 or DQ8) eat gluten (contained in cereals), it creates an inflammatory reaction that causes damage to the lining of the gut wall and does not allow food to be properly absorbed. People with CD also suffer from osteporosis, depression, infertility, and have increased risk to develop Type 1 diabetes and some cancers. In Canada, 330,000 persons currently have CD and the number of affected people continues to rise. We do not understand the reasons behind this increase. Our results using a unique animal model of gluten sensitivity that express the human genes that predispose to CD, suggest it may relate to changes in the microbes that reside in our gut. Thus, we propose to investigate the role of gut bacteria in gluten intolerance. We will use gluten-sensitive mice with no bacteria (germ-free) and we will colonize them with gut bacteria from patients with CD and healthy people.
There is no treatment for CD except for the gluten-free diet. This is a life-long commitment, not always effective and is very expensive for families as gluten-free foods are costly and not covered by the health care system. Moreover, it is not recommended in milder forms of gluten intolerance. This increases the possibility to progress from milder gluten intolerance to the severe condition of CD. We have developed a novel drug that binds to gluten in the gut lumen. We propose to investigate the mechanisms of action of this gluten binder in gluten-sensitive mice. Availability of safe therapies for gluten intolerance will add flexibility to the diet and increase the quality of life of gluten-sensitive patients as well as reduce the risks and health care costs associated with complications of CD and associated diseases such as Type 1 diabetes and cancer.
Competitiondate
201109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Verdu, Elena F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~